PDMR Dealing
LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on November 29, 2017, Dr. David Ebsworth, Non-Executive Chairman of the Company, purchased 10,000 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 106.85 pence per Ordinary Share. Following the acquisition, Dr. Ebsworth will have an interest in the Company of 135,787 Ordinary Shares, representing 0.13% of the Company’s issued share capital.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|||
| a) | Name | David Ebsworth |
||
| 2 | Reason for the notification |
|||
| a) | Position/status | Non-Executive Chairman |
||
| b) | Initial notification/Amendment | Initial notification |
||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||
| a) | Name | Verona Pharma plc |
||
| b) | LEI | 213800EVI6O6J3TIAL06 |
||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||
| a) | Description of the financial instrument, type of instrument |
Ordinary Shares of 5 pence each |
||
| Identification code | GB00BYW2KH80 | |||
| b) | Nature of the transaction | David Ebsworth purchased 10,000 Ordinary Shares | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| 106.85 pence per Ordinary Share | 10,000 Ordinary Shares | |||
| d) | Aggregated information | N/A |
||
| - Aggregated volume | ||||
| - Price | ||||
| e) | Date of the transaction | 29 November 2017 | ||
| f) | Place of the transaction | London Stock Exchange, AIM |
||
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive Officer | info@veronapharma.com |
| Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) |
Tel: +44 (0) 20 7710 7600 SNELVeronaPharma@stifel.com |
| Stewart Wallace / Jonathan Senior / Ben Maddison |
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
